CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Company
Eisai’s Urece Arrives in Shanghai, Poised for Chinese Market Entry
Eisai’s (TYO: 4523) China unit announced that the first batch of its innovative drug Urece...
Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability
France-based Sanofi (NASDAQ: SNY) announced plans to commence shipments of Beyfortus (nirsevimab) in early Q3...
Boai NKY’s LYC001 Receives Clinical Approval in China for Advanced Solid Tumors
China-based Boai NKY Medical Holdings Ltd (SHE: 300109) announced that its joint venture company, Beijing...
Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...
Jiangxi Rimag Plans Acquisition of Changsha Zhongya Medical for RMB 29.5 Million
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in...
Biogen Launches Qalsody in China for SOD1-ALS Treatment
US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...
Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH
Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...
WuXi Biologics Commences Construction on Microbial Production Base in Chengdu
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...
Sihuan Pharma’s Xuanyuening Granted New Indication Review in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases
US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...
Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion
Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...
ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...
Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...
Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System
Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...
Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...
Innovent Biologics’ Xinbiyue Approved for Macau Market
China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...
Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...
Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market
US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...